12:00 AM
 | 
Mar 15, 2010
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Ipsen, Menarini sales and marketing update

Ipsen and Menarini launched Adenuric febuxostat in France. The non-purine selective inhibitor of xanthine oxidase was approved in the EU in 2008 to treat chronic hyperuricemia...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >